Siegel Nelson CR, Knapp DA. 2000. Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians. Hypertension, 36:600–3. Nelson MR, Reid CM, Krum H, et al. 2003. Factors influencing family physician adherence to hypertension treatment guideline recommendations on the initiation of pharmacotherapy: questionnaire survey. Am J Cardiovasc Drugs, 3:437–41. [NHLBI] National Heart, Lung, and Blood Institute. 2003. National High Blood Pressure Education Program [online]. Accessed 9 Mar 2004. http://www.nhlbi.nih.gov/about/nhbpep/index.htm. Pahor M, Guralnik JM, Furberg CD, et al. 1996. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet, 347:1061–5. Pahor M, Guralnik JM, Salive ME, et al. 1996. Do calcium channel blockers increase the risk of cancer? Am J Hypertens, 9:695–9. Pearson TA, McBride PE, Miller NH, et al. 1996. Organization of preventive cardiology service. JACC, 27:1039–47. Psaty BM, Heckbert SR, Koepsell TD, et al. 1995. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA, 274:620–5. SHEP Cooperative Research Group. 1991. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA, 265:3255–64. Siegel D. 2000. The gap between knowledge and practice in the treatment and prevention of cardiovascular disease. Prev Cardiol, 3:167–71. Siegel D, Lopez J. 1997. Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing. JAMA, 278:1745–8. Siegel D, Lopez JR, Meier JL. 1998. Pharmacologic treatment of hypertension in the department of Veterans Affairs during 1995 and 1996. Am J Hypertens, 11:1271–8. Siegel D, Lopez, J, Meier J, et al. 2001. Changes in the pharmacologic treatment of hypertension in the department of Veterans Affairs 1997–1999: decreased use of calcium antagonists and increased use of β-blockers and thiazide diuretics. Am J Hypertens, 14:957–62. Siegel D, Lopez J, Meier J, et al. 2003. Academic detailing to improve antihypertensive prescribing patterns. Am J Hypertens, 16:508–11. Soumerai SB. 1988. Factors influencing prescribing. Aust J Hosp Pharm, 18(Suppl):9–16. Soumerai SB, McLaughlin TJ, Avorn J. 1989. Improving drug prescribing in primary care: a critical analysis of the experimental literature. Milbank Q, 67:268–317. Steiner JF, Koepsell TD, Fihn SD, et al. 1988. A general method of compliance assessment using centralized pharmacy records. Med Care, 26:814–23. The ALLHAT Offices and Coordinators for the ALLHAT Collaborative Research Group. 2002. Major outcomes in high-risk hypertensive patients randomized to angiotensin-coverting enzyme inhibitor or calcium channel blocker vs diuretic; the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALHAD). JAMA, 288:2981–97. Veterans Administration Cooperative Study Group on Antihypertensive Agents. 1970. Effect of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressures averaging 90 through 114 mmHg. JAMA, 213:1143–52. Walley T, Duggan AK, Haycox AR, et al. 2003. Treatment for newly diagnosed hypertension: patterns of prescribing and antihypertensive effectiveness in the UK. J R Soc Med, 96:525–31. Wilkes MS, Doblin BH, Shapiro MF. 1992. Pharmaceutical advertisements in leading medical journals: experts’ assessments. Ann Intern Med, 116:912–19. Ziegler MG, Lew P, Singer BC. 1995. The accuracy of drug information from pharmaceutical sales representatives. JAMA, 273:1296–8. 14 Vascular Health and Risk Management 2005:1(1)